Within the last decade, medical heart failure therapy has been broadened to the widespread use of angiotensin-converting-enzyme inhibitors (ACEI), aldosterone antagonists, angiotensin-neprilysin-inhibitors (ARNI) and, lately, SGLT-2 inhibitors, which all proved to reduce both mortality and heart-failure-related events [13,14,15]. The gene discussed is SLC5A2; the disease is heart failure.